Free Trial

kneat.com Q3 EPS Decreased by Raymond James Financial

kneat.com logo with Medical background

Key Points

  • Raymond James Financial has lowered their Q3 2025 earnings per share estimate for kneat.com to ($0.03), down from a previous forecast of $0.02.
  • The consensus estimate for kneat.com's full-year earnings currently stands at ($0.12) per share, with future earnings also forecasted to remain negative.
  • Kneat.com shares opened at C$6.02, with a market cap of approximately C$562.88 million and a PE ratio of -65.03.
  • Looking to Export and Analyze kneat.com Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

kneat.com, inc. (TSE:KSI - Free Report) - Research analysts at Raymond James Financial reduced their Q3 2025 earnings per share (EPS) estimates for shares of kneat.com in a report released on Tuesday, August 5th. Raymond James Financial analyst S. Li now forecasts that the company will post earnings per share of ($0.03) for the quarter, down from their prior estimate of $0.02. Raymond James Financial currently has a "Outperform" rating and a $7.00 target price on the stock. The consensus estimate for kneat.com's current full-year earnings is ($0.12) per share. Raymond James Financial also issued estimates for kneat.com's Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.04) EPS and FY2026 earnings at ($0.05) EPS.

kneat.com Stock Down 2.0%

Shares of TSE:KSI traded down C$0.12 on Friday, reaching C$5.90. The company had a trading volume of 574,272 shares, compared to its average volume of 93,188. kneat.com has a 52-week low of C$4.40 and a 52-week high of C$7.25. The firm's 50 day simple moving average is C$6.03 and its 200-day simple moving average is C$6.26. The firm has a market capitalization of C$551.66 million, a PE ratio of -63.73, a PEG ratio of 597.67 and a beta of 1.08. The company has a current ratio of 1.43, a quick ratio of 1.50 and a debt-to-equity ratio of 85.50.

About kneat.com

(Get Free Report)

kneat.com Inc is in the business of developing and marketing a software application for modelling regulated data-intensive processes for regulated industries, focusing on the life sciences industry. The company has developed Kneat Gx solution which provides management real-time visibility and control and increases product, quality, and compliance.

Featured Stories

Earnings History and Estimates for kneat.com (TSE:KSI)

Should You Invest $1,000 in kneat.com Right Now?

Before you consider kneat.com, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and kneat.com wasn't on the list.

While kneat.com currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines